Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Brexpiprazole

An atypical antipsychotic that modulates dopamine and serotonin receptors, approved in the United States in 2015 for schizophrenia and as add-on therapy in major depression. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.

Did you know?In 2023 it became the first medicine approved in the United States for agitation associated with Alzheimer's dementia, a symptom for which no medicine had previously been authorised.

BrexpiprazoleGo to the active ingredient →
BrexpiprazoleActive ingredientBrexpiprazoleCat. No. P-B104-001CAS 913611-97-9

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.